Barclays Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $917

Benzinga Newsdesk www.benzinga.com Negative 90.3%

Neg 90.3% Neu 0% Pos 0%

Barclays analyst Eliana Merle maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and lowers the price target from $923 to $917.